01 6Advate
02 4Kogenate
03 6Kogenate/Kovaltry/ Jivi
04 1KogenateTM
05 3Recombinate
06 1Refacto AF
07 8Refacto AF/Xyntha
08 1Refacto Af/Xyntha
Antihemophilic Factor (Recombinant)
Main Therapeutic Indication : Hematology
Currency : USD
2019 Revenue in Millions : 1,443
2018 Revenue in Millions : 0
Growth (%) : N/A
Antihemophilic Factor (Recombinant)
Main Therapeutic Indication : Rare Disorders
Currency : USD
2019 Revenue in Millions : 426
2018 Revenue in Millions : 514
Growth (%) : -17
Antihemophilic Factor (Recombinant)
Main Therapeutic Indication : Rare Disorders
Currency : USD
2020 Revenue in Millions : 1,029
2019 Revenue in Millions : 1,067
Growth (%) : -4
Antihemophilic Factor (Recombinant)
Main Therapeutic Indication : Hematology
Currency : USD
2020 Revenue in Millions : 1,253
2019 Revenue in Millions : 1,473
Growth (%) : -15
Antihemophilic Factor (Recombinant)
Main Therapeutic Indication : Rare Disorders
Currency : USD
2020 Revenue in Millions : 370
2019 Revenue in Millions : 426
Growth (%) : -13
Antihemophilic Factor (Recombinant)
Main Therapeutic Indication : Rare Disorders
Currency : USD
2021 Revenue in Millions : 906
2020 Revenue in Millions : 1,029
Growth (%) : -3
Antihemophilic Factor (Recombinant)
Main Therapeutic Indication : Hematology
Currency : USD
2021 Revenue in Millions : 1,019
2020 Revenue in Millions : 1,201
Growth (%) : -9
Antihemophilic Factor (Recombinant)
Main Therapeutic Indication : Rare Disorders
Currency : USD
2021 Revenue in Millions : 304
2020 Revenue in Millions : 370
Growth (%) : -18
Antihemophilic Factor (Recombinant)
Main Therapeutic Indication : Hematology
Currency : USD
2022 Revenue in Millions : 889
2021 Revenue in Millions : 906
Growth (%) : -2
Antihemophilic Factor (Recombinant)
Main Therapeutic Indication : Hematology
Currency : USD
2022 Revenue in Millions : 96
2021 Revenue in Millions : 81
Growth (%) : 18
